KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Kristin A Higgins, Chen Hu, Helen J Ross, Salma K Jabbour, David E Kozono, Taofeek K Owonikoko, Timothy A Ritter, Terence M Williams, James Welsh, Jeffry P Simko, B Movsas, Canhua Xiao, Kyoichi Kaira, Amit K Gupta, Pranshu Mohindra, Elie G Dib, Jeremy Brownstein, Stephen Chun, Charles S Kuzma, Rupesh Kotecha, Adedayo A Onitilo, Yuhchyau Chen, Thomas E Stinchcombe, Xiaofei Wang, Rebecca Paulus, Jeffrey D Bradley

J Clin Oncol 44(8) 630-640

PMID41529214
PMCIDPMC12874332
DOI10.1200/JCO-25-01569
发表日期2026-01-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG A1.:森林图/亚组分析图;FIG A2.:森林图/亚组分析图;FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图。
摘要

摘要

PURPOSE: NRG Oncology/Alliance LU005 (ClinicalTrials.gov identifier: NCT03811002) tested the addition of atezolizumab to concurrent chemoradiation (CRT) in this open-label, phase III international trial. METHODS: Patients with limited-stage small cell lung cancer (LS-SCLC), stage Tx-IV, N0-3, and M0 with Eastern Cooperative Group performance status (PS) 0-2 received one cycle of chemotherapy (platinum/etoposide) before study registration and were randomly assigned to CRT alone versus CRT plus concurrent and adjuvant atezolizumab, 1,200 mg once daily, every 3 weeks until investigator-assessed progression or intolerable side effects for a maximum of 17 cycles. Patients were stratified by choice of chemotherapy (cisplatin v carboplatin), radiation fractionation schedule (66 Gy once daily v 45 Gy twice daily), sex, and PS (0/1 v 2). The primary end point was overall survival (OS). Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate, local control, and distant-metastasis-free survival (DMFS). RESULTS: patients were randomly assigned from May 2019 to December 2023. The median OS was 36.1 months (95% CI, 28.1 to 42.5) for the CRT-alone arm and 31.1 months (95% CI, 28.5 to 44.7) for the CRT + atezolizumab arm, respectively (hazard ratio [HR], 1.03 [95% CI, 0.80 to 1.32]). The median PFS was 11.4 months (95% CI, 10.3 to 13.2) for the CRT-alone arm and 12.1 months (95% CI, 10.9 to 15.2) for the CRT + atezolizumab arm, respectively (HR, 0.98 [95% CI, 0.79 to 1.22]). The median DMFS was 13.0 months (95% CI, 11.3 to 18.2) for the CRT-alone arm and 16.8 months (95% CI, 12.1 to 21.6) for the CRT + atezolizumab arm (HR, 0.96 [95% CI, 0.76 to 1.21]). No unexpected safety signals with concurrent atezolizumab were observed. CONCLUSION: Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG A1.Forest plot of overall survival. AJCC, American Joint Committee on Cancer; BID, twice a day; CRT, chemoradiation; ECOG, Eastern Cooperative Group; HR, hazard ratio; RT, radiation therapy.
非 KM Figure
FIG A2.Forest plot of progression-free survival. AJCC, American Joint Committee on Cancer; BID, twice a day; CRT, chemoradiation; ECOG, Eastern Cooperative Group; HR, hazard ratio; RT, radiation therapy.
非 KM Figure
FIG 1.CONSORT diagram. CRT, chemoradiation; SCLC, small cell lung cancer.
非 KM Figure
FIG 2.Kaplan-Meier estimates of (A) OS, (B) progression-free survival, and (C) DMFS by treatment arm. HRs with 95% CIs are from stratified Cox proportional hazards models, stratified by as-randomized radiation schedule (BID v daily), chemotherapy regimen (cisplatin v carboplatin), and sex. Stratified log-rank tests provided P values for treatment comparisons. CRT, chemoradiation; DMFS, distant metastasis–free survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG 3.Overall survival by treatment arm according to (A) RT schedule (twice daily v daily, stratification factor), (B) PCI use (not randomized, exploratory analysis), and (C) chemotherapy regimen (cisplatin v carboplatin, stratification factor). Kaplan-Meier curves are shown for each treatment arm by factor level. Insets display HRs with 95% CIs for (1) the effect of atezolizumab within each factor level and (2) the effect of each factor within treatment arms. Interaction P values were estimated from Cox models including treatment arm, the factor of interest, and their interaction, stratified by the remaining random assignment strata. These analyses are exploratory and hypothesis-generating. CRT, chemoradiation; HR, hazard ratio; OS, overall survival; PCI, prophylactic cranial irradiation; RT, radiation therapy.
非 KM Figure